ACTRIMS-ECTRIMS: Ofatumumab Shows Efficacy in New MS Patients
Once-monthly injections allows patients to control their treatment schedule In a group of...
Read More
cid1399
Functional potential of gut microbiome in paediatric MS
No overall differences in the functional diversity of the gut microbiome were found in patients with pediatric-onset MS in a study using metagenomic sequencing. However, there were differences in the functional potential...
Read MoreGold nanocrystals may improve brain metabolic profile
Interim results from two phase 2 studies provide evidence that orally delivered CNM-Au8 (gold nanocrystals) have catalytic effects on key bioenergetic metabolites in the brain of patients with MS and Parkinson’s disease...
Read MoreCardiovascular risk factors linked to brain atrophy in younger MS patients
The presence of cardiovascular (CV) risk factors is associated with brain atrophy in relatively young MS patients under the age of 50. CV risk factors seem to have synergistic effects in MS. CV risk factors have been associated...
Read MorePredictive value of neurodegenerative CSF markers in MS
Cerebrospinal fluid (CSF) tau and beta-amyloid (Aβ) proteins are among the biomarkers currently applied in other neurodegenerative diseases than MS. Partly due to conflicting results, not a single biomarker of axonal damage in...
Read MoreInduction more effective than escalation as strategy in RRMS
An Italian study showed that long-term disability outcomes were more favourable with a strategy of early intensive treatment (EIT) than with moderate-efficacy treatment followed by escalation to higher-efficacy treatment (ESC)....
Read MoreLow-dose rituximab as effective as high-dose, but safer
Results of a Spanish two-center study suggest that low doses of rituximab are equally effective as high doses, but have a superior safety profile. The anti-CD20 monoclonal antibody rituximab is not registered for the treatment...
Read More
MS Relapses “Belong to the Past”
Ofatumumab Shows Efficacy & Safety in New MS Patients Only a few weeks prior to MSVirtual2020,...
Read More
Masitinib Impresses in Progressive MS
Perspectives from Patrick Vermersch, MD, Professor of Neurology at Lille University in France, and...
Read MoreACTRIMS-ECTRIMS: Phase 3 EXCHANGE, Insights From Lead Investigator
The interim analysis of the EXCHANGE trial suggest that, for patients with relapsing multiple sclerosis, immediate conversion from oral/injectable disease modifying therapies to siponimod without any washout period (within 24...
Read MoreECTRIMS 2020 Encore Event: NG-Specific Biomarkers Can Quickly Differentiate NMOSD from MS
Neutrophil granulocyte (NG)-specific biomarkers have high sensitivity and specificity for rapid differentiation between acute neuromyelitis optica spectrum disorders (NMOSD), anti-MOG-antibody associated disease (MOGAD), and...
Read MoreECTRIMS 2020 Encore Event: Interrupting DMT Due to Pregnancy Increases NfL Levels in MS
During pregnancy and the disease-modifying treatment (DMT)-free postpartum period, serum neurofilament-light (sNfL) levels were augmented [1]. This increase was independent of relapses, suggesting increased subclinical disease...
Read More